Listen To The Audio
From afar, 2020 looked very promising in all aspects from 2019 until it really met us. In fact, the Novel Coronavirus has really made life unbearable for many across the globe. One thing the world is waiting for is a remedy to salvage the COVID-19 menace.
Most countries have strived to seek medical breakthroughs for this Coronavirus issue and success seems to be hovering around in the air.
Now the first vaccine candidate from China has completed its phase-1 trial on humans, and the results have been put online for everyone’s perusal.
The Lancet, a respected medical journal in the UK, published the results on Friday saying it is “safe” and “induces a rapid immune response.”
The journal published:
The research injected the potential vaccine into 108 volunteers. They were divided into three groups, each taking a different dose of the vaccine. The vaccine, classified as “recombinant adenovirus type-5 vectored” (Ad5-nCoV), acts as a natural infection and is especially good at teaching the immune system how to fight the virus.
During the next 28 days, no serious reactions were found, meaning the vaccine seemed to be tolerable by humans.
Also, antibodies against the SARS-CoV-2 started to surge two weeks after the injection and reached its peak on day 28.
The vaccine “warrants further investigation,” the paper on The Lancet concluded. A phase-2 clinical trial has started with 508 volunteers involved.